热门资讯> 正文

赛默飞世科技深化对亚洲生物制药生态系统的投资

2025-12-03 13:24

赛默飞世尔(TMO) 0
stem(STEM) 0

Thermo Fisher Scientific (TMO) is expanding its bioprocessing operations in Asia amid the region’s rapidly growing biopharmaceutical industry, the company said on Tuesday.
The company is introducing a new bioprocess design center in Hyderabad, India, and has expanded its existing bioprocess design centers in Incheon, Korea, and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency, and sustainability in biomanufacturing.

More on Thermo Fisher Scientific

Thermo Fisher Scientific: More Upside Likely As Headwinds Continue To Fade And Valuation Still Attractive
Thermo Fisher: Recuperation And Macroeconomic Tailwinds Will Unlock Value
Thermo Fisher Scientific: Now Fairly Valued Considering Growth Outlook (Rating Downgrade)
Thermo Fisher Scientific prices €2.1B euro-denominated senior notes offering
Soroban acquires new stake in Union Pacific, closes out holdings in Duke Energy among Q3 moves

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。